Published November 09, 2012 by OSP
The United States remains the most common location for pediatric trials, according to a new study, despite some concerns that pediatric clinical trials are shifting to developing nations. Of 346 pediatric trials the FDA reviewed, the U.S. participated in 86 percent, providing three-quarters of the patients. However, some studies are more appropriate in developing nations, such as vaccine studies where the children can benefit from the new discoveries. Regardless of the location, Dr. Dianne Murphy, director of the FDA Office of Pediatric Therapeutics, argued for the importance, continuation, and necessity of clinical trials for children.